Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 3 of 48 · 2295 articles
Noninvasive blood indices are appealing because they’re easier than colonoscopy. This study tests whether two such indices (SII and HALP) reliably reflect endoscopic activity in ulcerative colitis and whether...
Children with IBD can develop idiopathic acute pancreatitis that is often mild but may recur; knowing this helps families and clinicians monitor and manage pancreatic symptoms during active disease and after surgery.
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study proposes new biomarker candidates (C5AR1, KDM2A, HCAR3) and microbiota-derived metabolites that might interact with those targets. If validated, that could guide future diagnostic tests or microbiome-targeted...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Symptoms and flares. The original article is from msn.com.
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when...
Researchers are exploring new small molecules that might modulate T cells in IBD. This study found lab evidence of T‑cell inhibition for several compounds but no therapeutic benefit in a mouse colitis model, so these...
People with IBD may care because this study connects a genetic risk region to a molecular mechanism that restrains inflammation in T cells, offering a potential new biological clue about disease causes and future...
The FDA label confirms triamcinolone acetonide injectable suspension is indicated for short-term use to manage flares in regional enteritis (Crohn’s disease) and ulcerative colitis and summarizes important safety and...
LRMDA may be a previously unrecognized protein important for mucus production and intestinal barrier integrity — processes directly relevant to IBD flares, infection risk, and colorectal cancer development. Understanding...
People with CGD commonly have liver involvement and some develop IBD-like intestinal disease; recognizing and monitoring these complications may affect care and outcomes.
If oxalate from common foods can worsen intestinal inflammation, people with IBD may need to consider how diet affects symptoms and disease activity. This research could point to new dietary counseling or therapies in...
The study links worse UC activity with higher rates of anxiety and depression and with poorer quality of life among patients in Pakistan, suggesting mental-health screening could be relevant to overall disease...
People with UC face higher cardiovascular risk; this study links a specific ITGA4 genetic variant (rs1143674 CC) with subclinical atherosclerosis in UC patients over 40, which could help identify higher-risk individuals...
People with ulcerative colitis considering or taking ozanimod or etrasimod may want to know about potential adverse events reported after these drugs entered the market, especially for nervous‑system, eye, and cardiac...
Insurance changes and rising premiums can force people with Crohn’s disease to skip or lose access to expensive biologic medications and routine care, which patients in the article say led to loss of treatment options...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Symptoms and flares. The original article is from Polish archives of internal medicine.
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
The work links a specific post-transcriptional regulator (AUF1) to barrier dysfunction in UC and demonstrates that AUF1-restored organoids can enhance mucosal repair in mice, suggesting a possible new regenerative...
Cure8 found this source from Evidence-based complementary and alternative medicine : eCAM, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open...
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...
The study tested whether early maternal or family adverse events increase later IBD risk and—using two large Scandinavian birth cohorts with registry follow-up—found no association. That may reassure families worried...
The study suggests acetate (sodium acetate) can protect intestinal cells and reshape the gut microbiota in preclinical models of ulcerative colitis, pointing to a potential microbiome-linked therapeutic avenue that might...
This study suggests an environmental fungicide can disrupt gut microbes and reduce beneficial microbial tryptophan metabolites, promoting colitis in mice; dietary tryptophan reversed those effects in the model.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
Microbiota-targeting treatments are an active area of IBD research, and biomaterials may help overcome delivery challenges that limit current microbiome therapies. Advances here could improve how well these approaches...
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...
The study suggests abdominal fat percentage (by DXA) is associated with fracture history in people with IBD, even after accounting for BMI, BMD, and lean mass. If confirmed prospectively, regional fat measures could help...
A new chemiluminescent probe may help researchers detect and visualize peroxynitrite, a reactive species linked to inflammation in ulcerative colitis, which could aid research into disease mechanisms and early detection...
Improving accuracy of IBD case identification in EMRs can make research and registries more reliable, reduce misclassification, and help ensure studies and quality programs use the right patient groups.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Cure8 indexed source-provided abstract text from CABI Publishing, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Inflammatory bowel disease and Medications.
This article reports that Amgen is ending a Crohn’s disease target-discovery collaboration with TScan, which could slow or change an industry pathway for immune-targeted therapies discovered through that partnership....
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...
The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...
A blood test that more reliably distinguishes UC from CD could reduce diagnostic uncertainty and help guide appropriate long‑term management for people with colonic inflammatory bowel disease.
People with IBD and their clinicians may be interested because some studies report higher prostate cancer incidence in IBD populations, and this review explores biological mechanisms that could explain a link while...
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
The trial could show whether a smart-label app plus clinician alerts improves medication adherence and downstream clinical outcomes for people with Crohn's disease or ulcerative colitis starting oral or subcutaneous...
A new Phase 3 trial is testing duvakitug as a potential induction therapy for moderate-to-severe ulcerative colitis. Trial results could add another treatment option if the drug proves safe and effective.
Researchers are testing whether baseline fecal microbiome profiles can predict who with mild ulcerative colitis will benefit from a specific prebiotic supplement. If validated, this approach could move dietary therapy...
The paper suggests a new molecular link—low ALIX expression—to inflammatory cell death (pyroptosis) that might help explain mucosal inflammation in ulcerative colitis. If validated, that pathway could point to biomarkers...
A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of...
Coexistence of ulcerative colitis and collagenous colitis is rare but can change diagnosis and management. Stool calprotectin and biopsies helped identify and monitor disease activity, and adjusting mesalazine coincided...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
